Literature DB >> 8495275

Differential effect of glucocorticoids on calcium absorption and bone mass.

C Gennari1.   

Abstract

Osteoporosis is one of the most serious side effects of glucocorticoid therapy and its development and severity are dependent on the particular glucocorticoid used. A short-term study (15 days) comparing the bone wasting effects and changes in calcium absorption induced by equiactive low and high doses of prednisone, deflazacort (DFZ) and betamethasone, revealed that low and high doses of betamethasone and high doses of prednisone induced a significant decrease in intestinal calcium absorption. No such changes were observed with DFZ. As 1,25-dihydroxycholecalciferol levels were maintained throughout the study, it appears that glucocorticoids impair calcium absorption through a mechanism not involving this hormone. A long-term study (1 year) of equipotent doses showed that all three glucocorticoids caused a decrease in calcium absorption and a progressive decrease in lumbar spine bone mineral content. However, the impairment of calcium absorption and decrease in bone mineral content was least with DFZ. Thus, DFZ appears to offer a degree of protection against both decreased calcium absorption and bone loss.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8495275     DOI: 10.1093/rheumatology/32.suppl_2.11

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  16 in total

Review 1.  Bone health and the female athlete triad in adolescent athletes.

Authors:  Kathryn E Ackerman; Madhusmita Misra
Journal:  Phys Sportsmed       Date:  2011-02       Impact factor: 2.241

2.  Periodontal disease and influence of periodontal treatment on disease activity in patients with rheumatoid arthritis and spondyloarthritis.

Authors:  Katarzyna Białowąs; Małgorzata Radwan-Oczko; Irena Duś-Ilnicka; Lucyna Korman; Jerzy Świerkot
Journal:  Rheumatol Int       Date:  2019-11-07       Impact factor: 2.631

3.  A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica.

Authors:  J H Healey; S A Paget; P Williams-Russo; T P Szatrowski; R Schneider; H Spiera; H Mitnick; K Ales; P Schwartzberg
Journal:  Calcif Tissue Int       Date:  1996-02       Impact factor: 4.333

Review 4.  Camurati-Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment.

Authors:  K Janssens; F Vanhoenacker; M Bonduelle; L Verbruggen; L Van Maldergem; S Ralston; N Guañabens; N Migone; S Wientroub; M T Divizia; C Bergmann; C Bennett; S Simsek; S Melançon; T Cundy; W Van Hul
Journal:  J Med Genet       Date:  2005-05-13       Impact factor: 6.318

5.  Deflazacort versus other glucocorticoids: a comparison.

Authors:  Surajit Nayak; Basanti Acharjya
Journal:  Indian J Dermatol       Date:  2008       Impact factor: 1.494

6.  Immunoglobulins as steroid sparing agents in chronic relapsing inflammatory optic neuropathy.

Authors:  Luis I Gonzalez-Granado
Journal:  Ann Indian Acad Neurol       Date:  2010-04       Impact factor: 1.383

Review 7.  Deflazacort. A review of its pharmacological properties and therapeutic efficacy.

Authors:  A Markham; H M Bryson
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 8.  Glucocorticosteroid-induced spinal osteoporosis: scientific update on pathophysiology and treatment.

Authors:  Albrecht W Popp; Juerg Isenegger; Elizabeth M Buergi; Ulrich Buergi; Kurt Lippuner
Journal:  Eur Spine J       Date:  2006-07       Impact factor: 3.134

9.  Clinical and radiological assessment of effects of long-term corticosteroid therapy on oral health.

Authors:  Swapna Sridevi Beeraka; Kannan Natarajan; Rajendra Patil; Rakesh Kumar Manne; Venkata Sarath Prathi; Venkata Suneel Kumar Kolaparthi
Journal:  Dent Res J (Isfahan)       Date:  2013-09

10.  Inhibitory effect of matrine on blood-brain barrier disruption for the treatment of experimental autoimmune encephalomyelitis.

Authors:  Su Zhang; Quan-Cheng Kan; Yuming Xu; Guang-Xian Zhang; Lin Zhu
Journal:  Mediators Inflamm       Date:  2013-09-08       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.